These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22754528)

  • 1. Inhibitory Monoclonal Antibodies against Mouse Proteases Raised in Gene-Deficient Mice Block Proteolytic Functions in vivo.
    Lund IK; Rasch MG; Ingvarsen S; Pass J; Madsen DH; Engelholm LH; Behrendt N; Høyer-Hansen G
    Front Pharmacol; 2012; 3():122. PubMed ID: 22754528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo.
    Lund IK; Jögi A; Rønø B; Rasch MG; Lund LR; Almholt K; Gårdsvoll H; Behrendt N; Rømer J; Høyer-Hansen G
    J Biol Chem; 2008 Nov; 283(47):32506-15. PubMed ID: 18799467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice.
    Jögi A; Rønø B; Lund IK; Nielsen BS; Ploug M; Høyer-Hansen G; Rømer J; Lund LR
    PLoS One; 2010 Sep; 5(9):e12746. PubMed ID: 20856796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
    Lund IK; Illemann M; Thurison T; Christensen IJ; Høyer-Hansen G
    Curr Drug Targets; 2011 Nov; 12(12):1744-60. PubMed ID: 21707477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
    Luther T; Magdolen V; Albrecht S; Kasper M; Riemer C; Kessler H; Graeff H; Müller M; Schmitt M
    Am J Pathol; 1997 Apr; 150(4):1231-44. PubMed ID: 9094980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
    Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
    Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
    Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun TC; Appella E; Danø K; Blasi F
    J Biol Chem; 1992 May; 267(13):9129-33. PubMed ID: 1315748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
    Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
    J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits.
    Florova G; Azghani A; Karandashova S; Schaefer C; Koenig K; Stewart-Evans K; Declerck PJ; Idell S; Komissarov AA
    Am J Respir Cell Mol Biol; 2015 Apr; 52(4):429-37. PubMed ID: 25140386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
    Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
    Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
    Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
    J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
    Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD
    Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
    Lund LR; Green KA; Stoop AA; Ploug M; Almholt K; Lilla J; Nielsen BS; Christensen IJ; Craik CS; Werb Z; Danø K; Rømer J
    EMBO J; 2006 Jun; 25(12):2686-97. PubMed ID: 16763560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activator supports liver repair independent of its cellular receptor.
    Shanmukhappa K; Sabla GE; Degen JL; Bezerra JA
    BMC Gastroenterol; 2006 Nov; 6():40. PubMed ID: 17134505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways.
    Schnaper HW; Barnathan ES; Mazar A; Maheshwari S; Ellis S; Cortez SL; Baricos WH; Kleinman HK
    J Cell Physiol; 1995 Oct; 165(1):107-18. PubMed ID: 7559792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The urokinase-type plasminogen activator system and its role in tumor progression].
    Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
    Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.